Ozempic prices set to crash as Semaglutide patent expires next week

India’s pharmaceutical sector is on the verge of a major transformation as the patent for semaglutide — the key ingredient behind blockbuster drugs like Ozempic and Wegovy — is set to expire on March 20.

The move is expected to unlock a flood of generic versions, dramatically changing access to diabetes and weight-loss treatments in one of the world’s largest patient markets.

Dozens of brands prepare for launch

Industry insiders say more than 50 branded generic versions could enter the market shortly after the patent expiry, marking one of the most crowded drug launches in recent years.

Major Indian pharmaceutical companies, including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Zydus Lifesciences and Lupin Limited, are gearing up for rapid rollout, with some already finalising supply and co-marketing deals.

Prices expected to fall sharply

Currently, semaglutide-based therapies in India can cost between Rs8,800 and Rs16,400 per month — a major barrier for most patients.

With generics entering the market, prices are expected to drop to around Rs3,000–4,000 initially, with further declines possible as competition intensifies.

This could translate into price cuts of up to 60–70% at launch, and potentially even deeper reductions over time.

Access expands, concerns remain

The expected price drop could significantly improve access for millions of patients dealing with type 2 diabetes and obesity — two rapidly growing health challenges in India.

However, experts are warning about the risks of misuse, particularly as semaglutide gains popularity as a weight-loss solution beyond medically recommended use.

Health authorities have already started tightening advertising rules to prevent misleading promotion and overuse.

A turning point for the pharma market

The patent expiry is being seen as more than just a pricing shift. It could redefine how advanced therapies are accessed in India, moving them from premium treatments to mainstream options.

At the same time, competition between global innovators like Novo Nordisk and local generic manufacturers is expected to intensify.

What comes next

As the March 20 deadline approaches, India is preparing for a rapid expansion in semaglutide availability.